H-2 Antigens pp 623-639 | Cite as

The Biological Implications of the Abnormal Expression of Histocompatibility Antigens on Murine and Human Tumors

  • Federico Garrido
Part of the NATO ASI Series book series (NSSA, volume 144)

Abstract

There is increasing evidence indicating that the expression of histocompatibility antigens is altered in experimental tumors induced in mice as well as in human tumors (1,2,). Two different types of alterations have been described:
  1. a)

    Total or selective loss of class I molecules (K,D,L or HLA, A,B,C) whose reexpression can in most cases be induced after γIFN treatment. Examples of this are absence of the Kk molecule of Gardner lymphoma (3) or the disappearence of four H-2d antigenic specificities on an H-2d sarcoma (4).

     
  • These losses may represent an escape route from T cell immunosurveillance or a mechanism to induce UK sensitive tumor targets, (19).

  1. b)

    The appearance of aberrant class I like molecules which may behave like alloantigens and are capable of triggering an immune response like that seen in allograft rejection (5,6). The aberrant molecules on these clones may be tumor associated transplantation antigen (TATA).

     

Keywords

Normal Mucosa Antigen Expression Tumor Associate Antigen Histocompatibility Antigen Clark Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    H. Festenstein, F. Garrido. MHC antigens and malignancy. Nature 322 502–503. (1986).PubMedCrossRefGoogle Scholar
  2. 2.
    H. Festenstein. The biological consequences of altered MHC expression on tumours. British Medical Bulletin 43,1, 217–227. (1987).Google Scholar
  3. 3.
    F. Garrido, H. Festenstein, V. Schirrmacher. Further evidence for derepression of H-2 and Ia-like specificities of foreign haplotypes in mouse tumour cell lines. Nature 261–705. (1976).Google Scholar
  4. 4.
    F. Garrido, M. Pérez, MdD. Torres. Absence of four H-2d antigenic specificities in an H-2 sarcoma. J. of. Immunogenetics 6, 83–86. (1979).CrossRefGoogle Scholar
  5. 5.
    V. Schirrmacher, D. Hübsch, F. Garrido. Syngeneic tumor cells can induce alloreactive T killer cells: A biological role for transplantation antigens. Proc. Natl. Acad. Sci. 77, 9, 5409–5413. (1980)PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    F. Garrido, M. Pérez, M.D. Torres, E. Garcia-Olivares, P. Ivanyi, V. Schirrmacher. A syngeneic anti tumor serum recognizing a complex H-2 alloantigen. Immunobiol. 156, 110–120. (1979).Google Scholar
  7. 7.
    H.J. Stauss, R. Linsk, A. Fischer, S. Watts, D. Banasiak, A. Haberman, I. Clark, J. Forman, M. McMillan, H. Schreiber, R.S. Goodenow. Isolation of the MHC genes encoding the tumour-specific class I antigens expressed on a murine fibrosarcoma. J. of Immunogenetics. 13, 101–111. (1986).CrossRefGoogle Scholar
  8. 8.
    R.S.Goodenow, J.M. Vogel, R.L. Linsk. Histocompatibility antigens on murine tumors. Science 230, 777. (1985).CrossRefGoogle Scholar
  9. 9.
    K. Hui, L. Minamide, N. Padroni, H. Festenstein, F.G. Grosveld. Structural variations in the H-2 genes AXE lymphomas. J. of Immunogenetics 13, 117–121. (1986).CrossRefGoogle Scholar
  10. 10.
    W. Schmidt, G. Noll, D. Bevec, U. Henseling. Aberrant MHC antigens in a sarcoma virus-induced mouse tumour. J. of Immunogenetics. 13, 123–132. (1986).CrossRefGoogle Scholar
  11. 11.
    A. Garrido, M. Pérez, C. Delgado, M.L. Garrido, J. Rojano, I. Algarra, F. Garrido. Influence of class I H-2 gene expression on local tumor growth. Exp. and Clinical Immunogenetics. 3, 98–110 (1986).Google Scholar
  12. 12.
    L. Eisenbach, S. Segal, M. Feldman. MHC imbalance and metastatic spread in Lewis lung carcinoma clones. International J. of Cancer 32, 113. (1983).CrossRefGoogle Scholar
  13. 13.
    M.L. Garrido, M. Pérez, C. Delgado, J. Rojano, I. Algarra, A. Garrido, F. Garrido. Immunogenicity of H-2 positive and H-2 negative clones of a mouse tumour GR9. J. of Immunogenetics. 13, 159–167. (1986).CrossRefGoogle Scholar
  14. 14.
    F.J. Bonal, E. Pareja, J. Martin, C. Romero, F. Garrido. Repression of class I H-2K, H-2D antigens on GR9 methylcholanthreneinduced tumour cell clones is related to the level of DNA methylation. 13, 179–186. (1986).Google Scholar
  15. 15.
    A. Caballero, MD. Collado, I. Algarra, A. Garrido, M. Pérez, F.rGarrido. H-2 antigen expression, tumor associated transplantation antigens any anti tumor CTL’s in clones derived from a chemically induced tumours. (in press) (1987).Google Scholar
  16. 16.
    C. Delgado, A. Garrido, M. Pérez, M.L. Garrido, I. Algarra, F. Garrido. Characterization of the syngeneic anti-tumour response against the GR9 tumour with the production of isoantisera and monoclonal antibodies. J. of Immunogenetics. 13, 169–177. (1986).CrossRefGoogle Scholar
  17. 17.
    A. Watson, F.H. Bach. The role of gp70 in the target antigen recognized by murine leukemia virus immune cytotoxic T-lymphocytes. Int. J. Cancer. 26, 483. (1980).PubMedCrossRefGoogle Scholar
  18. 18.
    E. Pareja, E. Canadas, C. Romero, J. Martin M.J. Mialdea, F. Garrido. MHC-DNA class I gene transfection and expression in a murine class I negative tumour cell clone. Inmunologia (in press). (1987).Google Scholar
  19. 19.
    M. Pérez, T. Cabrera, M.A. Lopez Nevot, M. Gomez, F. Peran, F. Garrido. Heterogeneity of the expression of class I and II HLA antigens in human breast carcinoma. J.of Immunogenetics. 13, 247–253Google Scholar
  20. 20.
    H.G. Ljunggren, K. Kärre. Experimental strategies and interpretations in the analysis of changes in MHC gene expression during tumour progression: opposing influences of T cell natural killer cell mediated resistance. J. of Immunogenetics. 13, 141–151. (1986)CrossRefGoogle Scholar
  21. 21.
    M.A. Lopez Nevot, E. Garcia, E. Pareja, F.J. Bonal, J. Martin, F. Differential expression of HLA class I and II antigens in primary and metastatic melanomas. J. of Immunogenetics. 13, 219–227. (1986).CrossRefGoogle Scholar
  22. 22.
    J. Gutierrez, M.A. Lopez Nevot, T. Cabrera, R. Oliva, J. Esquivias F. Ruiz-Cabello, F. Garrido. Class I and II HLA antigen distribution in normal mucosa, adenoma and colon carcinoma: Relation with malignancy and invasiveness. Clin. and Exp. Immunogenetics (in press. (1987).Google Scholar
  23. 23.
    M. Pérez, A. Garrido, I. Algarra, F. Garrido. Different H-2 phenotypes in clones derived from a new BALB/c solid tumor. Its relevance for local tumor growth. Inmunologia. 4,2, 60–69. (1985).Google Scholar
  24. 24.
    P.I. Schrier, R. Bernards, R.T.M.J. Vaessen, A. Houweling, A.J. Van Der Eb. Expression of class I major histocompatibility antigens swiched off by highly oncogenic adenovirus 12 in transformed rat cells. Nature. 305, 771. (1983).PubMedCrossRefGoogle Scholar
  25. 25.
    F. Momburg, P. Möller, G. Moldenhauer, G.J. Hämmerling. Loss of HLA-A,B,C, in colorectal carcinoma is related to the degree of de-differentiation. J. of Immunogenetics. 13, 195–199. (1986).CrossRefGoogle Scholar
  26. 26.
    F. Ruiz-Cabello, M.A. Lopez Nevot, J. Gutierrez, A. Ferron, F. Esteban, C. Rivas, M.A. Piris, F. Garrido. Phenotypic expression of histocompatibility antigens in human primary tumors and metastases. Cancer Research. (in press). (1987).Google Scholar
  27. 27.
    M.A. Lopez Nevot, T. Cabrera, B. de la Higuera, F. Ruiz-Cabello F. Garrido. Production and characterization of monoclonal antibodies against human leukaemia cells. Inmunologia. 5, 2. 51–59. (1986).Google Scholar
  28. 28.
    T. Cabrera, F. Ruiz-Cabello, M.A. Lopez Nevot, B. de la Higuera, M. Sanchez, F. Garrido. Characterization of monoclonal antibodies directed against HLA class II molecules. Hybridoma. 5,3, 191–197. (1986).Google Scholar
  29. 29.
    A. Ziegler, B. Uchanska-Ziegler, G. Rosenfelder, D.G. Braun, P. Wernet. Heterogeneity of established human hematopoietic cell lines: Surface antigens detected by monoclonal antibodies and glycosphilipid patterns. In: Leukaemia markers. Proceedings of the leukaemia marker conference held in Vienna. Academic Press. 137. (1981).Google Scholar
  30. 30.
    A.J. Watson, R. Demars, I.S. Trowbridge, F.H. Bach. Detection of a novel human HLA antigen. Nature. 304, 358–361. (1983).PubMedCrossRefGoogle Scholar
  31. 31.
    D.J. Ruiter, W. Bergman, K. Welvaart, E. Scheffer, W.A. van Vloten C. Russo, S. Ferrone. Immunohistological analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. Cancer Res. 44, 3930. (1984).PubMedGoogle Scholar
  32. 32.
    E.B. Bröcker, L. Suter, J. BrUggen, D.J. Ruiter, E. Macher, C. Sorg. Phenotypic dynamics of tumor progression in human malignant melanoma. Int. J. of Cancer. 36, 29. (1985).CrossRefGoogle Scholar
  33. 33.
    F. Ruiz-Cabello, M.A. Lopez Devot, F. Garrido. MHC class I and II gene expression on human tumors. Cancer Metastasis, Bolonia, Italy Plenum Publishing Corporation. (In press). May 13–15 (1987).Google Scholar
  34. 34.
    P.L. Stern, N. Beresford, S.M. Bell, S. Thompson, K. Jones, A. Mellor. Murine embryonal carcinoma cells express class I MHC like antigens. J. of Immunogenet. 13, 133. (1986).CrossRefGoogle Scholar
  35. 35.
    G.J. Hämmeling, D. Klar, S. Katzav, S. Segal, M. Feldman, R. Wallich, A. Hämmerling. Manipulation of metastasis and tumor growth by transfection with histocompatibility class I genes. J. of Immunogenet. 13, 153. (1986).CrossRefGoogle Scholar
  36. 36.
    F. Garrido, V. Schirrmacher, H. Festenstein. H-2 like specificities of foreign haplotypes appearing on a mouse sarcoma after vaccinia virus infection. Nature. 259, 5540, 228–230. (1976).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1987

Authors and Affiliations

  • Federico Garrido
    • 1
  1. 1.Servicio Análisis ClínicosHospital Virgen de las NievesGranadaSpain

Personalised recommendations